Asia Pacific Respiratory Therapeutic Devices Market

Asia Pacific Respiratory Therapeutic Devices Market Size

The size of the Asia Pacific respiratory therapeutic devices market was worth USD 2.11 billion in 2024. The Asia Pacific market is anticipated to grow at a CAGR of 5.45% from 2025 to 2033 and be worth USD 19.52 billion by 2033 from USD 12.77 billion in 2025.

The Asia Pacific respiratory therapeutic devices are a broad range of medical equipment designed to diagnose, monitor, and treat respiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, sleep apnea, and cystic fibrosis. These devices include nebulizers, ventilators, continuous positive airway pressure (CPAP) machines, oxygen concentrators, inhalers, and peak flow meters. According to the World Health Organization, air pollution contributes to nearly 7 million premature deaths annually globally with the Asia Pacific region accounting for a significant portion of this burden. In countries like India and China, rapid urbanization and industrial emissions have led to deteriorating air quality, directly increasing the prevalence of respiratory ailments. As per the Indian Council of Medical Research, respiratory diseases rank among the top five causes of hospitalization in India, with a critical need for effective therapeutic interventions. Furthermore, Japan’s rapidly aging population has intensified the prevalence of age-related lung disorders such as pneumonia and bronchitis, prompting increased adoption of home-based respiratory support systems. In Australia, rising investments in sleep disorder diagnostics have boosted CPAP usage, while government initiatives in Southeast Asian nations are improving access to affordable oxygen therapy solutions.

MARKET DRIVERS

Rising Prevalence of Chronic Respiratory Diseases

One of the most significant drivers contributing to the growth of the Asia Pacific respiratory therapeutic devices market is the steep rise in chronic respiratory diseases such as COPD, asthma, and interstitial lung disease. According to the Global Burden of Disease Study, respiratory illnesses accounted for over 10% of total deaths in the Asia Pacific in 2023, with COPD and lower respiratory infections being the leading contributors. In China alone, the Chinese Center for Disease Control and Prevention reported that more than 100 million individuals suffer from COPD, which is making it one of the most prevalent non-communicable diseases in the country.

This growing disease burden has resulted in higher patient reliance on therapeutic devices such as nebulizers, oxygen concentrators, and CPAP machines to manage symptoms and improve quality of life. In India, the Indian Chest Society noted that asthma rates have increased by nearly 20% over the past decade, particularly in metropolitan cities affected by high levels of vehicular emissions and industrial pollutants. Moreover, governments across the region are recognizing the economic and social impact of prolonged respiratory illness and have begun integrating device-assisted therapies into national treatment protocols.

Increasing Adoption of Home-Based Respiratory Care

Another major factor fueling the growth of the Asia Pacific respiratory therapeutic devices market is the shift toward home-based respiratory care, driven by rising healthcare costs and a preference for outpatient treatment models. Hospitals and clinics are increasingly recommending self-administered therapies using CPAP machines, oxygen concentrators, and handheld nebulizers to reduce inpatient admissions and alleviate the burden on healthcare facilities. In Japan, where the population aged above 65 exceeds 30%, the Ministry of Health, Labour and Welfare has actively promoted home oxygen therapy and tele-homecare services to support elderly patients suffering from chronic respiratory failure. Similarly, in Australia, the National Asthma Council has endorsed the use of personal peak flow meters and smart inhaler technology to empower patients with real-time monitoring capabilities. In emerging economies like Thailand and Malaysia, private insurers and government-backed programs are increasingly covering home-use respiratory devices by encouraging broader adoption. This trend is reshaping market dynamics, prompting manufacturers to develop compact, user-friendly, and cost-effective respiratory solutions tailored for home environments across diverse APAC demographics.

MARKET RESTRAINTS

High Cost of Advanced Respiratory Devices in Low-Income Populations

A major restraint impeding the widespread adoption of respiratory therapeutic devices in the Asia Pacific region is the high cost associated with advanced products such as CPAP machines, bilevel positive airway pressure (BiPAP) systems, and portable oxygen concentrators. As per the World Health Organization, in several parts of Southeast Asia, less than 10% of respiratory patients can afford long-term device therapy without financial assistance, which is limiting market penetration despite growing disease prevalence. Additionally, maintenance and replacement costs, such as filters, masks, and batteries, further add to the economic burden, discouraging sustained use. Public funding mechanisms and subsidy programs remain underdeveloped in many APAC nations, which restricts access to essential respiratory treatments.

Limited Reimbursement Policies and Insurance Coverage

Another significant challenge affecting the Asia Pacific respiratory therapeutic devices market is the limited reimbursement policies and insufficient insurance coverage for respiratory care products in many regional healthcare systems. Unlike in developed markets such as the United States and Europe, where government and private insurers often cover a substantial portion of device costs, many APAC countries lack structured reimbursement frameworks for home-based respiratory therapies. In India, despite the expansion of Ayushman Bharat, coverage for CPAP machines and oxygen concentrators remains minimal, with most benefits restricted to hospital-acquired treatments rather than outpatient device purchases.

MARKET OPPORTUNITIES

Expansion of Telehealth and Remote Patient Monitoring for Respiratory Conditions

An emerging opportunity driving the Asia Pacific respiratory therapeutic devices market is the rapid expansion of telehealth and remote patient monitoring solutions, particularly in the management of chronic respiratory diseases. Healthcare providers are increasingly leveraging connected devices to track patient symptoms, adherence, and therapy outcomes beyond traditional clinical settings with advancements in digital health technologies. In South Korea, the Ministry of Health and Welfare launched a national initiative promoting “smart homecare” through IoT-enabled inhalers and spirometry devices that transmit real-time data to physicians. According to the Korean Institute of Medical Information, remote monitoring of COPD and asthma patients increased by 35% between 2021 and 2023, reducing emergency room visits and hospitalizations. India has also seen growing adoption of mobile-based respiratory tracking apps, especially in tier-2 and tier-3 cities where access to specialists is limited. Companies like ResApp Health and Apollo Telehealth are partnering with device manufacturers to embed diagnostics into smartphone-compatible accessories.

Growing Demand for Portable and Compact Respiratory Devices

The increasing demand for portable and compact respiratory therapeutic devices presents a significant opportunity for market players in the Asia Pacific region. In Japan, where domestic travel among the elderly is common, companies like Panasonic and Omron expanded their product lines to include ultra-lightweight devices suitable for train and air travel. In Australia, the rise in adventure tourism and long-distance travel has prompted travelers with asthma and COPD to seek portable nebulizers and spirometers for use during flights and outdoor excursions. The Lung Foundation Australia reported that nearly 30% of respondents with chronic respiratory conditions preferred portable devices for ease of use during travel, which is influencing purchasing behavior. Moreover, startups in India and Indonesia are introducing affordable, miniaturized nebulizers compatible with smartphones, enabling caregivers to administer treatments even in remote locations. This shift toward portability is generating new revenue streams and encouraging manufacturers to invest in ergonomic and user-centric design improvements across APAC markets.

MARKET CHALLENGES

Regulatory Complexity and Diverse Approval Pathways Across APAC Countries

One of the primary challenges facing the Asia Pacific respiratory therapeutic devices market is the regulatory complexity and fragmented approval processes across different countries. Unlike the streamlined systems in the European Union or the United States, the APAC region comprises multiple regulatory authorities, each with distinct requirements for device classification, registration, and clinical validation.

In China, the National Medical Products Administration mandates extensive local trials even for devices approved abroad, causing delays that can extend beyond 12 months. Similarly, in Malaysia, evolving guidelines issued by the Medical Device Authority create uncertainty for foreign suppliers attempting to navigate compliance procedures. These inconsistencies make it difficult for global manufacturers to standardize their product offerings and distribution strategies. Smaller firms, in particular, face resource constraints when attempting to comply with multiple sets of regulations, thereby limiting their ability to scale operations efficiently.

Lack of Skilled Healthcare Professionals for Proper Device Usage and Maintenance

Another significant challenge affecting the Asia Pacific respiratory therapeutic devices market is the shortage of trained healthcare professionals capable of guiding patients in the correct usage and maintenance of complex respiratory equipment. While device manufacturers introduce increasingly sophisticated technology, such as smart inhalers and connected CPAP machines, end-user education remains inadequate in rural and semi-urban areas.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Product Insights

The oxygen concentrators segment was the largest and held 28.1% of the Asia Pacific respiratory therapeutic devices market share in 2024 due to the rising prevalence of chronic respiratory diseases across the region. According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) remains one of the leading causes of death globally, with India and China alone contributing to over 3 million deaths annually due to air pollution and tobacco use. Additionally, the surge in respiratory illnesses post-pandemic has significantly increased home-based oxygen therapy usage. Another major contributor to the growth of this segment is the increasing geriatric population, especially in countries like Japan and South Korea, where the percentage of individuals aged 65 and above exceeds 28%.

The ventilator segment is projected to grow with an expected CAGR of 11.7% in the coming years. The impact of the COVID-19 pandemic on hospital infrastructure cannot be overstated. Countries across the APAC region, particularly India, China, and Indonesia, significantly expanded their ICU capacities. According to the Indian Ministry of Health and Family Welfare, ICU beds in India grew by over 45% between 2020 and 2023, directly boosting ventilator demand. Simultaneously, there has been a surge in homecare ventilation systems, especially in urbanized economies like Japan and Australia. The rise in neuromuscular disorders and chronic respiratory failure has increased prescriptions for non-invasive ventilation at home. Moreover, manufacturers are entering into partnerships and local manufacturing agreements to meet rising demand. For example, Medtronic signed joint ventures in Vietnam and Thailand to produce ventilators locally, reducing import dependency and cost barriers.

By Application Insights

The Chronic Obstructive Pulmonary Disease (COPD) segment accounted in holding 35.6% of the Asia Pacific respiratory therapeutic devices market share in 2024. According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), an estimated 100 million people in China suffer from COPD, making it the second-leading cause of death in the country. In India, the situation is equally alarming, with nearly 55 million adults affected by COPD, as reported by the Public Health Foundation of India. In addition to disease prevalence, the aging population in developed APAC countries like Japan and South Korea further fuels demand for COPD treatment devices. The elderly are more susceptible to progressive lung deterioration, necessitating long-term therapeutic interventions such as inhalers, oxygen concentrators, and PAP devices. Investments in early detection and treatment programs have also risen sharply. For example, the Japanese government launched “Breath for Life,” a national campaign promoting spirometry screening in primary care centers. Such initiatives enhance diagnosis rates and subsequent device uptake.

The Obstructive Sleep Apnea (OSA) segment is lucratively to grow with a CAGR of 12.2% from 2025 to 2033. Sleep apnea has traditionally been underdiagnosed in many APAC countries; however, recent campaigns and medical education programs have improved recognition. In Australia, for instance, the Sleep Health Foundation estimates that over 2 million Australians suffer from OSA, with less than 20% diagnosed prior to 2010. Now, thanks to government-backed awareness efforts and digital health apps, diagnosis rates have surged. Further, telemedicine platforms and home sleep testing kits have made OSA diagnosis more accessible, especially in rural areas of India, Indonesia, and the Philippines. Companies like ResMed and BMC Medical have launched affordable CPAP devices tailored for APAC consumers.

KEY MARKET PLAYERS

Some of the noteworthy companies in the APAC respiratory therapeutic devices market profiled in this report are Hill-Rom Services Inc. (Baxter), ResMed Inc., Drägerwerk AG & Co. KGaA, Hamilton Medical, Koninklijke Philips N.V., VYAIRE MEDICAL, INC., Invacare Corporation, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Breas Medical AB, ICU Medical, Medtronic, Fisher & Paykel Healthcare Limited, and GE Healthcare.

COUNTRY LEVEL ANALYSIS

China Respiratory Therapeutic Devices Market Insights

China was the top performer in the Asia Pacific respiratory therapeutic devices market with 32.1% of the share in 2024. Air pollution remains a major public health concern in China, with the Institute for Health Metrics and Evaluation (IHME) reporting that ambient particulate matter pollution contributes to over 800,000 premature deaths annually. This environmental burden has led to a sharp increase in COPD, asthma, and other chronic respiratory conditions, consequently boosting demand for therapeutic devices like oxygen concentrators and nebulizers. Additionally, the Chinese government’s push for self-reliance in medical technology under the “Made in China 2025” initiative has spurred local manufacturing of respiratory devices. Domestic players like Yuwell and Mindray have emerged as global competitors, offering cost-effective alternatives to imported products. The expansion of private healthcare networks and insurance coverage has also improved access to respiratory care. According to the National Healthcare Security Administration, over 95% of China's population now has basic health insurance coverage, enabling broader utilization of therapeutic devices.

Japan Respiratory Therapeutic Devices Market Insights

Japan occupies the second-largest position in the Asia Pacific respiratory therapeutic devices market with a market share of around 18% in 2023. According to Japan’s National Institute for Longevity Medical Research, more than 28% of the population is aged 65 or older, making Japan the world’s most aged society. Japan’s regulatory framework is also conducive to innovation and the adoption of new technologies. The Pharmaceuticals and Medical Devices Agency (PMDA) ensures timely approvals for high-quality respiratory devices, encouraging both domestic and international companies to enter the market. Companies like Fukuda Denshi and Omron Healthcare play pivotal roles in shaping the local device ecosystem. Moreover, home healthcare is gaining popularity in Japan due to hospital bed shortages and cultural preferences for aging at home.

India Respiratory Therapeutic Devices Market Insights

India's respiratory therapeutic devices market is anticipated to grow with the highest CAGR in the coming years. India suffers from severe air quality issues, with multiple cities consistently ranking among the world's most polluted. According to IQAir data, Delhi recorded an average PM2.5 level of 96.4 µg/m³ in 2022, nearly ten times the WHO-recommended limit. This poor air quality has led to a significant spike in respiratory illnesses. The Indian government’s Ayushman Bharat scheme, covering over 500 million citizens, has greatly improved access to critical respiratory care services. Alongside this, startups and small enterprises are innovating in the space of affordable home oxygen devices and nebulizers, supported by Make in India and Digital India initiatives. Moreover, the post-pandemic health consciousness has triggered demand for personal respiratory devices.

Australia Respiratory Therapeutic Devices Market Insights

Australia's respiratory therapeutic devices market is likely to grow with prominent growth opportunities in the coming years. Australia has one of the highest prevalence rates of asthma globally, with Asthma Australia reporting that nearly 2.7 million people live with the condition. The country also boasts a robust reimbursement framework. Under Medicare, continuous positive airway pressure (CPAP) devices are partially subsidized for diagnosed sleep apnea patients, significantly lowering out-of-pocket expenses. Furthermore, Australia leads in digital integration with telehealth and connected respiratory devices. Internationally renowned brands like ResMed and Fisher & Paykel Healthcare have strong footholds in the Australian market and are expanding into other APAC regions from here.

South Korea Respiratory Therapeutic Devices Market Insights

South Korea's respiratory therapeutic devices market is prominently growing with its technological prowess. South Korea offers a unique blend of advanced healthcare infrastructure, high R&D investment, and government-backed health initiatives. The Korean government plays a crucial role in fostering innovation through agencies like the Korea Health Industry Development Institute (KHIDI), funding research into next-generation respiratory devices. South Korea's Ministry of Food and Drug Safety (MFDS) has also streamlined approval processes, encouraging faster commercialization of novel products. Additionally, smart health tech is booming in South Korea. Integrations between wearable sensors, mobile apps, and cloud-connected devices allow real-time monitoring of respiratory parameters. Samsung and LG are investing heavily in IoT-enabled health products, creating synergies between consumer electronics and medical devices.

TOP LEADING PLAYERS IN THE MARKET

Philips (Netherlands-based)

Philips is a global leader in healthcare technology and plays a significant role in shaping the respiratory therapeutic devices market. In the Asia Pacific region, Philips has a strong presence through its wide range of products, including CPAP machines, oxygen concentrators, and ventilators. The company focuses on innovation and digital health integration, offering connected solutions that enhance patient monitoring and therapy outcomes. It collaborates with local healthcare providers and governments to improve access to respiratory care across both urban and rural areas.

ResMed (United States-based)

ResMed is a dominant player in sleep and respiratory care, particularly known for its CPAP and non-invasive ventilation devices. In the Asia Pacific market, ResMed has strategically expanded its footprint through localized product development, strategic partnerships, and distribution networks. The company emphasizes home-based therapy solutions, which aim to support the rising demand for portable and user-friendly respiratory devices. Its focus on telehealth and remote patient monitoring aligns well with evolving healthcare trends in the region.

Fisher & Paykel Healthcare (New Zealand-based)

Fisher & Paykel Healthcare is a key contributor to respiratory care in the Asia Pacific region, especially recognized for its humidification and respiratory support systems. The company provides innovative solutions for both hospital and homecare settings, focusing on improving patient comfort and treatment adherence. With a strong R&D base and tailored product offerings, it caters to diverse clinical needs across countries with varying healthcare infrastructures. Its commitment to sustainability and clinical education further strengthens its regional influence.

TOP STRATEGIES USED BY KEY MARKET PARTICIPANTS

One major strategy employed by leading players is product innovation and technological advancement. Companies are investing heavily in developing next-generation respiratory devices that offer better usability, connectivity, and patient compliance. These innovations often include smart features such as real-time monitoring, data analytics, and compatibility with mobile applications. Another crucial approach is strategic partnerships and collaborations. Firms are engaging in joint ventures, distributor agreements, and academic alliances to expand their reach and integrate complementary technologies. Lastly, companies are focusing on localized manufacturing and supply chain optimization. By establishing production facilities or partnering with local manufacturers, firms can reduce costs, ensure regulatory compliance, and respond more effectively to regional demand fluctuations. This localization strategy supports faster deployment and improved accessibility across diverse healthcare systems.

COMPETITIVE LANDSCAPE

The competitive landscape in the Asia Pacific respiratory therapeutic devices market is marked by a mix of global multinationals and rapidly growing domestic players. Established companies leverage their strong brand recognition, extensive distribution networks, and continuous innovation to maintain dominance. However, local manufacturers are gaining traction by offering cost-effective alternatives tailored to regional healthcare needs. The market is highly fragmented, especially in developing economies where affordability and accessibility play critical roles. Competition is not only centered on pricing but also extends to product differentiation, ease of use, and integration with digital health platforms. Mergers, acquisitions, and strategic collaborations are increasingly common as companies aim to strengthen their regional foothold. Additionally, there's a growing emphasis on expanding into tier-2 and tier-3 cities, where untapped potential exists due to rising disposable incomes and increasing awareness about respiratory health. Innovation remains a key differentiator, with firms racing to develop smarter, more efficient devices that cater to both hospital and homecare environments.

RECENT MARKET DEVELOPMENTS

• In September 2023, Philips launched a new line of portable oxygen concentrators specifically designed for the Asian market, targeting homecare users in rural and semi-urban regions. This move is aimed at addressing the growing demand for accessible and affordable respiratory support outside of hospital settings.
• In November 2023, ResMed partnered with a leading Australian telehealth provider to integrate its CPAP therapy devices with remote patient monitoring systems by enhancing personalized care delivery and improving treatment adherence among OSA patients across the APAC region.
• In February 2024, Fisher & Paykel Healthcare announced the expansion of its manufacturing facility in Malaysia to boost local production capacity, which is supporting increased demand for humidification and respiratory support devices in Southeast Asia.
• In May 2024, Yuwell Medical, a key Chinese manufacturer, entered into a strategic collaboration with a Japanese distributor to expand its presence in Japan by leveraging local expertise to introduce its range of nebulizers and oxygen concentrators into new market segments.

In July 2024, GE Healthcare divested part of its respiratory care portfolio to acquire a niche digital diagnostics firm by signaling a strategic shift toward integrating AI-driven tools into respiratory disease management, particularly relevant for hospital-based applications in the Asia Pacific.

MARKET SEGMENTATION

This Asia Pacific respiratory therapeutic devices market research report is segmented and sub-segmented into the following categories.

By Product

• Positive airway pressure (PAP) devices
  • Continuous positive airway pressure (CPAP) devices
  • Auto-titrating positive airway pressure (APAP) devices
  • Bi-level positive airway pressure (BiPAP) devices
• Oxygen concentrator
  • Fixed oxygen concentrators
  • Portable oxygen concentrators
• Ventilators
  • Adult ventilators
  • Neonatal ventilators
• Inhalers
  • Metered dose inhaler (MDI)
  • Dry powder inhaler (DPI)
  • Soft mist inhaler (SMI) 
• Nebulizers
  • Compressor-based nebulizers
  • Piston-based hand-held nebulizers
  • Ultrasonic nebulizers
• Humidifiers
  • Heated humidifiers
  • Passover humidifiers
  • Integrated humidifiers
  • Built-in humidifiers
  • Standalone humidifiers  
• Others

By Application

• COPD
• Obstructive sleep apnea
• Asthma
• Respiratory distress syndrome
• Cystic fibrosis
• Others

By End-use

• Hospital
• Homecare settings
• Emergency centers

By Country

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest Of APAC